论文部分内容阅读
胸腺素α_1(Ta_1)是一种免疫调节剂,它能诱导淋巴细胞成熟、增强T细胞功能、促进免疫缺陷的重建。近年来单用或与干扰素(IFN)联合应用治疗慢性乙型、丙型和丁型肝炎取得一定效果。现将Tα_1的应用疗效作一综述。 一、治疗乙型肝炎疗效评价 1991年MutchnicK等最早进行的一项Ⅱ期临床试验认为80％的慢性乙型肝炎(CHB)病人经Tα_1治疗后达到临床、血清学及组织学改善。然而,到了1995年仍由MutchnicK主持的一项多中心研究显示97例Tα_1治疗病人与对照组疗效仅略有差异。1996年Andreone等对
Thymosin alpha 1 (Ta_1) is an immunomodulator that induces lymphocyte maturation, enhances T cell function, and promotes the reconstruction of immunodeficiency. In recent years alone or with interferon (IFN) combined treatment of chronic hepatitis B, C and D hepatitis achieved some results. Now Tα_1 the application of efficacy are reviewed. First, the treatment of hepatitis B efficacy evaluation In 1991 MutchnicK such as a phase II clinical trial that 80% of chronic hepatitis B (CHB) patients after Tα_1 treatment to achieve clinical, serological and histological improvement. However, by a multicenter study that was still channeled by MutchnicK in 1995, there was only a slight difference in efficacy between the 97 Tα_1-treated patients and the control group. Andreone et al